PT-141 dosing chart (mg to units)
PT-141 appears in PinPoint as the generic compound bremelanotide, described in the library as a melanocortin receptor agonist. Its peptide entry has an FDA-approved status tag and a 10 mg catalog vial. Five vial fractions provide the amount-to-units comparisons here. The cited prescribing information is for Vyleesi.
Vial concentration
Water mL is treated as final solution mL in these columns.
| Vial contents | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 10 mg | 10 mg/mL10 U-100 units per mg | 5 mg/mL20 U-100 units per mg | 3.3333 mg/mL30 U-100 units per mg |
Vial source: PinPoint/Data/CompoundLibrary.swift, line 712, the PT-141 entry. One documented amount is available.
Amount to units
Example amounts (arithmetic only, not doses).
| Amount (mg) | 10 mg + 1 mL | 10 mg + 2 mL | 10 mg + 3 mL |
|---|---|---|---|
| 0.2 mg | 2 units | 4 units | 6 units |
| 0.5 mg | 5 units | 10 units | 15 units |
| 1 mg | 10 units | 20 units | 30 units |
| 2 mg | 20 units | 40 units | 60 units |
| 5 mg | 50 units | 100 units | 150 unitsover one syringe |
Cited amounts
| Amount (mg) and source context | Frequency as stated | Route as stated | 10 mg + 1 mL | 10 mg + 2 mL | 10 mg + 3 mL | Source |
|---|---|---|---|---|---|---|
| 0.75 mg2017 blood-pressure study in premenopausal women. | Two administrations separated by 24 hours | Subcutaneous | 7.5 units | 15 units | 22.5 units | Bremelanotide blood-pressure study, Journal of Hypertension (2017)Peer-reviewed studyRetrieved 2026-10-05 |
| 1.25 mg2017 blood-pressure study in premenopausal women. | Two administrations separated by 24 hours | Subcutaneous | 12.5 units | 25 units | 37.5 units | Bremelanotide blood-pressure study, Journal of Hypertension (2017)Peer-reviewed studyRetrieved 2026-10-05 |
| 1.75 mgLabel amount for premenopausal women with acquired, generalized HSDD. | As needed, at least 45 minutes before sexual activity; at most once per 24 hours and 8 times monthly | Subcutaneous | 17.5 units | 35 units | 52.5 units | Bremelanotide prescribing information (Vyleesi)Regulatory labelRetrieved 2026-10-05 |
How to read this chart
Find the concentration column. Divide the amount by that concentration. Multiply the mL value by 100 for U-100 units. Match the amount units before dividing.
units = amount ÷ (vial mg ÷ water mL) × 100
Amount and volume
One mg equals 1,000 mcg; 100 U-100 units equals 1 mL. Concentration connects amount to volume. Read the full conversion guide.
The stored value and its source annotation
The PT-141 half-life used by the library is 2.5 hours. Its prescribing-label source annotation also mentions an approximately 2.7-hour terminal half-life. This page reports the stored 2.5-hour model input rather than silently replacing it with the nearby reference number. Keeping that distinction visible makes the profile traceable to the app. Either duration is expressed in hours, whereas the volume table is independent of elapsed time: a 10 mg vial divided by 2 mL remains 5 mg per mL throughout the calculation.
Peak timing in an event log
PinPoint records a one-hour time-to-peak parameter and a base bioavailability coefficient of 0.85 for PT-141. That coefficient is 85% when displayed as a percentage. The administration-route list contains subcutaneous, paired with a compounded-vial delivery form. The event's timestamp is what places the modeled rise on the log's timeline. An amount recorded at one clock time and the same amount recorded hours later produce differently positioned estimates even though their concentration and syringe-volume arithmetic can be identical.
Frequency text without a repeating weekly pattern
The PT-141 common-frequency field contains the labels As needed and Not more than once in 24h. Those are the library's stored descriptions, rather than a single recurring weekday interval. This makes the actual sequence of logged timestamps especially useful when reviewing the record. PinPoint's model has its own hour-based parameters regardless of how entries are spaced on the calendar. The chart does not infer a weekly total from those labels; it presents individual mg amounts and their corresponding liquid volumes.
A catalog vial expressed in portions
The 10 mg package reference comes from a supplier catalog describing a lyophilized PT-141 vial. Its example rows are 0.2, 0.5, 1, 2, and 5 mg. Consider the 1 mg portion: it is a tenth of the vial's contents, so its volume is a tenth of each column's solution volume. That gives 0.1, 0.2, and 0.3 mL, or 10, 20, and 30 U-100 units. The half-vial row of 5 mg follows the same relationship but reaches 1.5 mL in the final column.
Questions about the conversion
What concentration is PT-141 at 10 mg in 1 mL?
10 mg divided by 1 mL is 10 mg per mL. That volume spans 100 U-100 syringe units.
How does 2 mL change the concentration of this PT-141 vial?
10 mg divided by 2 mL is 5 mg per mL, half the concentration in the 1 mL column.
What does the 3 mL column mean for PT-141?
10 mg divided by 3 mL is approximately 3.3333 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.
How many units is 1 mg of PT-141 from this vial in 2 mL?
1 mg divided by 5 mg per mL is 0.2 mL, or 20 U-100 units.
How many units is the 0.75 mg cited amount of PT-141 from a 10 mg vial in 2 mL?
The arithmetic is 0.75 mg ÷ 5 mg/mL × 100 = 15 U-100 units (0.15 mL). The amount is cited in Bremelanotide blood-pressure study, Journal of Hypertension (2017). 2017 blood-pressure study in premenopausal women.
Track your calculations in the app
PinPoint for iOS brings vial setup, unit conversion, dose logs, site rotation, and protocol tracking together. Enter vial size and water volume for concentration and syringe units, then log injections with compound, dose, site, and pain level.
Get PinPoint on the App Store